Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 results, with a 43% drop in revenue year-over-year. The company highlighted progress in its AI-driven drug discovery platform, but faces cash burn risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results